Chargement en cours...
Development of Novel Diclofenac Analogs Designed to Avoid Metabolic Activation and Hepatocyte Toxicity
[Image: see text] Diclofenac (DCF) is widely used as a nonsteroidal anti-inflammatory drug; however, it is associated with severe liver injury. This adverse reaction is thought to be related to the reactive quinone imine (QI) and acyl glucuronide (AG) metabolites of DCF, but it remains controversial...
Enregistré dans:
| Publié dans: | ACS Omega |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Chemical Society
2020
|
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7758955/ https://ncbi.nlm.nih.gov/pubmed/33376898 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.0c04942 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|